Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
—
—
—
—
—
—
1 Year
Score—
Net Growth—
Net Trend—
Net Income Consistency—
Rev Growth—
Rev Trend—
Revenue Consistency—
5 Years
—
—
50%
—
—
75%
—
5 Years
Score—
Net Growth—
Net Trend50%
Net Income Consistency—
Rev Growth—
Rev Trend75%
Revenue Consistency—
Explore the 2021 public Archive ranking →
Where Teva Pharma Industries Ltd ADR has ranked, year by year
Measure
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- TEVA
2001: 17.4% · 2021: 98.1% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 38.88 | — |
1 Year2025-09-26 | $ 18.34 | 112.00% |
5 Years2021-09-28 | $ 9.60 | 305.00% |
10 Years2016-09-28 | $ 46.66 | -16.68% |
20 Years2006-09-28 | $ 26.55 | 46.42% |
30 Years1996-09-27 | $ 3.57 | 10x |
All Time1990-03-26 | $ 0.40 | 96x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1990-03-26 |
|---|---|---|---|---|---|---|---|
| Price | $ 38.88 | $ 18.34 | $ 9.60 | $ 46.66 | $ 26.55 | $ 3.57 | $ 0.40 |
| Return | — | 112.00% | 305.00% | -16.68% | 46.42% | 10x | 96x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | |||
| 2025 | $ 17.25B | $ 1.41B | $ 3.55B |
| 2024 | $ 16.54B | -$ 1.63B | $ 3.30B |
| 2023 | $ 15.84B | -$ 559M | $ 3.22B |
| 2022 | $ 14.92B | -$ 2.44B | $ 2.80B |
| 2021 | $ 15.87B | $ 417M | $ 2.16B |
| 2020 | $ 16.65B | -$ 3.99B | $ 2.17B |
| 2019 | $ 16.88B | -$ 999M | $ 1.97B |
| 2018 | $ 18.85B | -$ 2.15B | $ 1.78B |
| 2017 | $ 22.38B | -$ 16.26B | $ 963M |
| 2016 | $ 21.90B | $ 329M | $ 988M |
| 2015 | $ 19.65B | $ 1.58B | $ 6.94B |
| 2014 | $ 20.27B | $ 3.05B | $ 2.22B |
| 2013 | $ 20.31B | $ 1.26B | $ 1.03B |
| 2012 | $ 20.31B | $ 1.96B | $ 2.87B |
| 2011 | $ 18.31B | $ 2.75B | $ 1.09B |
| 2010 | $ 16.12B | $ 3.33B | $ 1.28B |
| 2009 | $ 13.89B | $ 2.00B | $ 2.24B |
| 2008 | $ 11.08B | $ 635M | $ 1.90B |
| 2007 | $ 9.40B | $ 1.95B | $ 2.87B |
| 2006 | $ 8.40B | $ 546M | $ 2.04B |
| 2005 | $ 5.25B | $ 1.07B | $ 2.21B |
| 2004 | $ 4.79B | $ 331M | $ 1.04B |
| 2003 | $ 3.27B | $ 691M | $ 1.37B |
| 2002 | $ 2.51B | $ 410M | $ 1.04B |
| 2001 | $ 2.07B | $ 278M | $ 790M |
| 2000 | $ 1.74B | $ 148M | $ 424M |
| 1999 | $ 1.28B | $ 117M | $ 94M |
| 1998 | $ 1.11B | $ 68M | $ 49M |
| 1997 | $ 1.11B | $ 101M | $ 58M |
| 1996 | $ 953M | $ 73M | $ 69M |
| 1995 | $ 667M | $ 79M | $ 73M |
| 1994 | $ 587M | $ 71M | $ 50M |
| 1993 | $ 502M | $ 57M | $ 39M |
| 1992 | $ 406M | $ 32M | $ 13M |
| 1991 | $ 327M | $ 23M | $ 7M |
| IPO1990 | $ 329M | $ 20M | $ 15M |
Teva Pharma Industries Ltd ADR fundamental performance
Across Teva Pharma Industries Ltd ADR's full reported history, from 1990 to 2025, revenue grew from $ 329M to $ 17.25B and net income grew from $ 20M to $ 1.41B. Revenue increased in 71% of the years measured; net income in 60%.
Membership
Continue TEVA’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
